ATE390127T1 - Universelle zusammensetzung zur kontrollierten wirkstoffabgabe enthaltend chitosan - Google Patents

Universelle zusammensetzung zur kontrollierten wirkstoffabgabe enthaltend chitosan

Info

Publication number
ATE390127T1
ATE390127T1 AT03019532T AT03019532T ATE390127T1 AT E390127 T1 ATE390127 T1 AT E390127T1 AT 03019532 T AT03019532 T AT 03019532T AT 03019532 T AT03019532 T AT 03019532T AT E390127 T1 ATE390127 T1 AT E390127T1
Authority
AT
Austria
Prior art keywords
active
controlled
containing chitosan
delivery containing
composition
Prior art date
Application number
AT03019532T
Other languages
English (en)
Inventor
Adnan Ali Badwan
Mayyas Mohammad Ahma Al-Remawi
Mutaz Bellah A W Salem
Original Assignee
Jpm The Jordanian Pharmaceutic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jpm The Jordanian Pharmaceutic filed Critical Jpm The Jordanian Pharmaceutic
Application granted granted Critical
Publication of ATE390127T1 publication Critical patent/ATE390127T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03019532T 2003-09-01 2003-09-01 Universelle zusammensetzung zur kontrollierten wirkstoffabgabe enthaltend chitosan ATE390127T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03019532A EP1512394B1 (de) 2003-09-01 2003-09-01 Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan

Publications (1)

Publication Number Publication Date
ATE390127T1 true ATE390127T1 (de) 2008-04-15

Family

ID=34130084

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03019532T ATE390127T1 (de) 2003-09-01 2003-09-01 Universelle zusammensetzung zur kontrollierten wirkstoffabgabe enthaltend chitosan

Country Status (5)

Country Link
US (1) US20050281873A1 (de)
EP (1) EP1512394B1 (de)
JP (1) JP2005075831A (de)
AT (1) ATE390127T1 (de)
DE (1) DE60319983T2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007136083A1 (ja) * 2006-05-24 2007-11-29 Meiji Dairies Corporation 液状食品増粘化剤及びその製造法
WO2010062261A1 (en) * 2008-11-29 2010-06-03 The Thailand Research Fund System and method for preparing a controlled releas preparation
CN103211789B (zh) * 2012-01-18 2017-07-11 北京天衡药物研究院有限公司 盐酸氨溴索膜控缓释微丸胶囊
JP6566970B2 (ja) * 2014-06-04 2019-08-28 リカルダ、リミテッド、ライアビリティ、カンパニーＬｉｋａｒｄａ，Ｌｌｃ マイクロカプセル化技術及びその生成物
US10660945B2 (en) 2015-08-07 2020-05-26 Victor Matthew Phillips Flowable hemostatic gel composition and its methods of use
US10751444B2 (en) 2015-08-07 2020-08-25 Victor Matthew Phillips Flowable hemostatic gel composition and its methods of use
CN105380925A (zh) * 2015-12-08 2016-03-09 青岛正大海尔制药有限公司 氨溴索沙丁胺醇控释颗粒
CZ2016539A3 (cs) * 2016-09-05 2018-03-14 Zentiva, K.S. Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy
CN110179764B (zh) * 2019-06-24 2022-01-11 哈尔滨珍宝制药有限公司 一种盐酸氨溴索片及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187703B1 (de) * 1985-01-11 1992-08-05 Teijin Limited Präparate mit verzögerter Freisetzung
US5600565A (en) * 1994-12-22 1997-02-04 International Business Machines Corporation Method and apparatus for error reduction in item packaging
US5620706A (en) * 1995-04-10 1997-04-15 Universite De Sherbrooke Polyionic insoluble hydrogels comprising xanthan and chitosan
US5859419A (en) * 1995-09-28 1999-01-12 Sol H. Wynn Programmable multiple company credit card system
CA2243619A1 (fr) * 1998-07-17 2000-01-17 Universite De Sherbrooke Hydrogels polyioniques a base de xanthane et chitosane pour stabilisation et relargage controle des vitamines
US20020029176A1 (en) * 2000-09-01 2002-03-07 Anne Carlson Inventory management system and method

Also Published As

Publication number Publication date
EP1512394A1 (de) 2005-03-09
US20050281873A1 (en) 2005-12-22
DE60319983D1 (de) 2008-05-08
DE60319983T2 (de) 2009-07-23
EP1512394B1 (de) 2008-03-26
JP2005075831A (ja) 2005-03-24

Similar Documents

Publication Publication Date Title
BR0307893A (pt) Formulação oftálmica com sistema de goma
AR036943A1 (es) Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
DK1315479T3 (da) Pektin-filmkompositioner
NO20016107L (no) Mesalazin-kontrollert frigivelse orale farmasöytiske sammensetninger
ATE313586T1 (de) Mehrarmige blockcopolymere und pharmazeutische zusammensetzung
WO2007070677A3 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
EP0966966A3 (de) Nefazodon enthaltende Dosierungsform
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
WO2005072343A3 (en) Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use
DE60313359D1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
WO2003074086A1 (fr) Matrice liquide a transfert de phase in vivo, et preparations liquides orales
ATE390127T1 (de) Universelle zusammensetzung zur kontrollierten wirkstoffabgabe enthaltend chitosan
NO20010863L (no) Nye orale formuleringer for 5-HT4-agonister eller - antagonister
TNSN03141A1 (fr) Formulation pharmaceutique au gout masque et son procede de preparation
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
WO2004078111A3 (en) Extended release minocycline compositions and processes for their preparation
NO20064808L (no) Orale matrixformuleringer med licarbazepin
WO2008055254A3 (en) Formulations and methods for oral delivery of proteins
DE60108354D1 (de) 2H-1-Benzopyran-Derivative, Prozesse zu ihrer Herstellung und Pharmazeutische Zusammensetzungen
JO2571B1 (en) A general composition of controlled liberation
ZA200705660B (en) Pharmaceutical polymer composition for oral controlled-release delivery of terbutaline sulfate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties